Financial Performance - Revenue for Q3 2024 reached ¥1,101,865,551.67, an increase of 16.31% year-over-year, with year-to-date revenue at ¥3,269,282,916.66, up 22.07% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2024 was ¥34,959,769.18, reflecting a 17.41% increase year-over-year, while year-to-date net profit reached ¥107,929,607.48, up 22.62%[3] - The company reported a basic earnings per share of ¥0.0874 for Q3 2024, an increase of 17.41% year-over-year, with year-to-date earnings per share at ¥0.2698, up 18.54%[3] - Total operating revenue for the current period reached CNY 3,269,282,916.66, an increase from CNY 2,678,296,897.28 in the previous period, representing a growth of approximately 22.05%[17] - Net profit for the current period was CNY 115,866,292.21, compared to CNY 88,631,391.41 in the previous period, indicating a growth of approximately 30.67%[18] - Total profit for the current period was CNY 148,217,065.80, compared to CNY 117,941,004.49 in the previous period, representing an increase of approximately 25.67%[18] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥4,960,958,944.75, representing a 7.57% increase from the end of the previous year[3] - Total liabilities rose to CNY 2,935,983,821.11, compared to CNY 2,635,167,802.36, reflecting an increase of approximately 11.4%[16] - The company's total equity increased to CNY 2,024,975,123.64 from CNY 1,976,530,117.29, showing a growth of approximately 2.4%[16] - The total current liabilities increased to CNY 2,166,988,583.95 from CNY 1,963,735,209.65, reflecting an increase of about 10.4%[16] Cash Flow - The company’s cash flow from operating activities for the year-to-date period was ¥393,835,456.88, an increase of 28.18% compared to the same period last year[3] - The net cash flow from operating activities for Q3 2024 was ¥393,835,456.88, an increase of 28.2% compared to ¥307,255,936.08 in Q3 2023[21] - Total cash inflow from operating activities decreased to ¥3,498,385,903.66 from ¥4,183,043,515.41, representing a decline of 16.4% year-over-year[21] - Cash outflow from operating activities also decreased to ¥3,104,550,446.78, down 20% from ¥3,875,787,579.33 in the previous year[21] - The ending balance of cash and cash equivalents was ¥314,375,619.08, down from ¥592,623,124.05 in the previous year[21] Research and Development - Research and development expenses for Q3 2024 increased by 138.46% to ¥21,099,674.53, driven by enhanced drug development and information technology initiatives[8] - Research and development expenses increased to CNY 21,099,674.53 from CNY 8,848,463.74, marking a significant rise of about 138.66%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,048, with the top 10 shareholders holding a combined 70.12% of shares[9] - He Jiale holds 50.12% of shares, amounting to 200,493,326 shares, with 51,000,000 shares pledged[10] - Alibaba Health Technology (China) Co., Ltd. holds 7.51% of shares, totaling 30,049,373 shares[11] - The top 10 unrestricted shareholders include Alibaba Health with 30,049,373 shares and Huatai Zijin Investment with 19,650,575 shares[12] - The company maintains a strong shareholder base with significant stakes held by both individual and institutional investors[9] Investment Income - The company’s investment income surged by 196.05% to ¥1,251,299.74, mainly from investments in bank wealth management products[8] - Investment income for the current period was CNY 1,251,299.74, compared to CNY 422,666.24 in the previous period, indicating a growth of approximately 195.66%[18] Inventory and Operating Costs - The company’s inventory rose by 8.81% to ¥840,088,361.33, attributed to an increase in retail store numbers and stock preparation[7] - The company’s operating costs for Q3 2024 were ¥2,209,430,174.00, reflecting a 20.55% increase due to higher sales revenue[8] - Total operating costs amounted to CNY 3,133,754,849.95, up from CNY 2,573,336,182.13, reflecting an increase of about 21.73%[17] Audit Information - The company did not undergo an audit for the Q3 report[22]
华人健康(301408) - 2024 Q3 - 季度财报